PubMed=11819844; DOI=10.3748/wjg.v7.i5.630
Li Y., Tang Z.-Y., Ye S.-L., Liu Y.-K., Chen J., Xue Q., Chen J., Gao D.-M., Bao W.-H.
Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.
World J. Gastroenterol. 7:630-636(2001)
PubMed=15048980; DOI=10.1002/pmic.200300653
Ding S.-J., Li Y., Shao X.-X., Zhou H., Zeng R., Tang Z.-Y., Xia Q.-C.
Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials.
Proteomics 4:982-994(2004)
PubMed=15146329; DOI=10.1007/s00432-004-0564-9
Li Y., Tian B., Yang J., Zhao L., Wu X., Ye S.-L., Liu Y.-K., Tang Z.-Y.
Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics.
J. Cancer Res. Clin. Oncol. 130:460-468(2004)
PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)
PubMed=25690035; DOI=10.3390/ijms16024209
Tian M.-M., Cheng H., Wang Z.-Q., Su N., Liu Z.-X., Sun C.-Q., Zhen B., Hong X.-C., Xue Y., Xu P.
Phosphoproteomic analysis of the highly-metastatic hepatocellular carcinoma cell line, MHCC97-H.
Int. J. Mol. Sci. 16:4209-4225(2015)
PubMed=25886575; DOI=10.1186/s12885-015-1166-4
Dang H., Steinway S.N., Ding W., Rountree C.B.
Induction of tumor initiation is dependent on CD44s in c-Met(+) hepatocellular carcinoma.
BMC Cancer 15:161-161(2015)
PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)
PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)
400 179 0116
